News and Comments

One Year Accomplishments Vs. One Cent Missed in Agenus Financial Report

  Thursday, March 03, 2016

Agenus (AGEN) is a project in the making since the firm has decided to play an integral part in immuno-oncology, doing everything possible towards building checkpoint modulator antibodies, in addition to its protective and therapeutic vaccines.    More...

Exelixis: Great News Towards Great Changes

  Tuesday, March 01, 2016

Exelixis’ (EXEL) quarterly results beat analysts’ expectations, which was the least of our concerns. The details of the firm’s actions during the past year, however, confirmed our conviction that the recently approved products will be taken care of responsibly by the firm that created them and believed in them against all pessimistic opinions.  More...

AERIE Pharmaceuticals: The Novel Glaucoma Eye Drops Confirm Their Superiority

  Thursday, February 18, 2016

On February 4, 2015, under the title “Airie Pharmaceuticals is speeding towards improving the treatment of glaucoma”, we wrote the following under News & Comments in the Prohost Website: More...

Regulus Offers Proof of Concept and Feasibility with Its HCV RNA Targeted Drug

  Wednesday, February 17, 2016

Regulus Pharmaceuticals (RGLS) a biopharmaceutical company that discovers, designs and develop treatments targeting microRNAs announced interim results from one of the company's ongoing Phase 2 studies of its hepatitis C virus (HCV) product RG-101.   More...

Knowing Better About Gilead and Amgen. The Mess and Miss Following the Storm

  Friday, February 05, 2016

Gilead Sciences More...

Dana-Farber Institute and Array Pharmaceutical Scientists to Work Together

  Tuesday, February 02, 2016

Yes. Dana-Farber Cancer Institute and Array Pharmaceuticals (ARRY) announced an immuno-oncology collaboration with potential applicability in a wide range of cancer indications.    More...

Exelixis has Good News About CABO

  Thursday, January 28, 2016

EXELIXIS More...

The Two Pianists. Breakthrough in the Diagnosis and Treatment of Diseases. See also Illumina

  Monday, January 11, 2016

The Evolution of Liquid Biopsy More...

Who Skipped the Bloody Market? Why Gilead Embarked on Galapagos NV Drug Filgotonib?

  Monday, January 04, 2016

The market looks like angry, probably very angry, as stocks are in a severe selloff mood. There will be many explanations like usual, but it is difficult for us to speculate this time over the correctness of the offered explanations, including the Iran Saudi Arabia crisis, which led to an increase in the oil price whose decrease has caused the previous market’s bad mood.    More...

ARRAY Rallies On Successful NEMO trial Results Of Binetinib on NRAS-Mutant Melanoma

  Wednesday, December 16, 2015

When you do your due diligence, you do not lose your faith in what you believed in giving up to the hype that’s sprayed around you. We were happy today to hear Array BioPharma (ARRY) report that results from the Phase 3 NEMO clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma. The trial met its primary endpoints.  More...


Recent Postings


Archive


Tags

PTC Therapeutics (PTCT) Human Longevity (HLI) GUARDIAN HEALTH Exelixis (EXEL) Agenus (AGEN Tysabri Gilead (GILD) Sangamo (SGMO) Idenix (IDIX) Array Pharmaceuticals (ARRY) Vertex (VRTX) Auspex (ASPX) Pluristem (PSTI) Roche (ROCHE) Dynavax (DVAX) ABBVIE (ABBV) NANTKWEST (NK) Ziofpharm (ZIOP) ACADIA (ACAD) Human Genome Sciences (HGSI) GlaxoSmithKline (GSK) Illumina (ILMN) Prosensa (RNA) Sanofi (SNY) C4 Therapeutics TOKAI (TKAOI) Spike Therapeutics (ONCE) Incyte (INCY) NEKTAR (NKTR)) Velcade (bortezomib) Intercept (ICPT) BIOMARIN (BMRN) Prolor Biotech (PBTH) Benlysta (belimumab) Trastuzumab-DM1 KITE (KITE) Seattle Genetics (SGEN) Theravance (THRX) Biocryst (BCRX) Bristol-Myers Squibb (BMY) Sanofi-Aventis (SAN) Mirati Therapeutics (MRTX) Intrexon (XON) Telaprevir galapagos (GLPG) AGOS (ARGS) ADVENTRIX (ANX) Sarepta (SRPT) Jazz Pharmaceuticals (JAZZ) Sanofi (SNA) Anacor (ANAC) ARCA (ABIO) ZALTRAP™ VANDA (VNDA) Zerenex Ridaforolimus Regeneron (REGN) Micromet (MITI) Biogen Idec (BIIB) RenenxBio (RGNX) Elan (ELN) KERYX (KERX) Editas (EDIT) ARGOS (ARGS) SYNTA (SNTA) Theravance Bio Pharma (TBPH) JUNO (JUNO) Abbott Laboratories (ABT) AERIE PHARMACEUTICALS INNOVIVA (INVA) Roche (RHHBY) ImmunoGen (IMGN) CompuGen (CGEN) Cytokinetics (CYTK) HALOZYME (HALO) Xoma (XOMA) Agenus (AGEN) Merck (MRK) Ariad (ARIA) Aimmune Therapeutics (AIMT) Genentech Multiple Myeloma Sequenom (SQNM) Endometrial Cancer Alnylam (ALNY) Anadys (ANDS) Vitae Pharmaceuticals (VTAE) ISIS (ISIS) REGULUS (RGLS) Intermune (ITMN) Valeant Pharmaceuticals International (VRX) SUNESIS PHARMACEUTICALS (SNSS) Revlimid (lenolidamide) OSI (OSIP) Inovio (INO) Alder Biopharmaceuticals (ALDR) Herceptin Rapamune Ionis (IONS) Onyx (ONXX) Dendreon (DNDN) SERES THERAPEUTICS (MCRB) Galena (GALE) IDERA (IDRA) Amgen (AMGN) Global Cell Therapeutics (GBT)